Anagenics Limited · ASX:AN1
Anagenics — Cellmid — Investor Presentation (April 2018)
31 slides from Anagenics's investor presentation, April 2018
Slide 1: Investor Presentation
INVESTOR PRESENTATION CEO Maria Halasz APRIL 2018 ASX: CDY
Slide 2: Australian life science company
Australian life science company with a risk managed portfolio of scientifically- backed, first and best in class technologies, operating in high growth and high value sectors. Two portfolios: Revenue generating consumer products in anti-aging and a promising biotechnology business focused on novel t
Slide 3: Company Overview
COMPANY OVERVIEW • Three wholly owned subsidiaries, each with a portfolio of innovative IP: • Advangen (consumer health): first in class, best in class anti- aging functional cosmetics. First product - a novel FGF5 inhibiting hair cycle regulator clinically validated to reduce hair loss and increase
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS Risk managed Life Science portfolio with high growth opportunities already generating revenue Proprietary, Exposure to the fast Recent strategic Midkine drug Business plan for Highly experienced clinically validated growth anti-aging agreement to portfolio growth- New Board and
Slide 5: Advangen
CELLMID © ADVANGEN Positive Aging
Slide 6: Leading Anti-Aging Portfolio
LEADING ANTI-AGING PORTFOLIO A leader in the development and marketing of novel and clinically validated anti-aging functional cosmetics and consumer health products for hair, face and wellbeing Advangen’s core focus is anti-aging A differentiated market consumer health products proposition • Anti-a
Slide 7: Advangen has delivered strong revenue growth to date
Advangen has delivered strong revenue growth to date, with 2018 a breakout year with full marketing CAGR 57% launch of key products across multiple markets Acquired in 2013 (FY2014) from Japanese owners with revenues increasing 4X since acquisition Products sold in three key markets -Japan, Australi
Slide 8: Leading Anti-Aging Portfolio
LEADING ANTI-AGING PORTFOLIO • FGF5 is a naturally occurring protein and critical in the hair cycle • Its role is to signal hair to stop growing • Blocking FGF5 can extend the growth phase of hair resulting in increased hair growth, reduced hair loss and longer, stronger and thicker hair • evolis® i
Slide 9: Product Portfolio
PHARMACY Reverse Prevent SALON / Promote PROFESSIONAL JAPAN / CHINA PRODUCT PORTFOLIO
Slide 10: Distribution Agreement
DISTRIBUTION AGREEMENT • Entered into agreement with Labo International to undertake the exclusive distribution of Fillerina® in AU & NZ in April 2018 • First non-injectable transdermal filler that has been clinically validated to reduce wrinkles and increase facial volume • International market lea
Slide 11: Key Achievements
KEY ACHIEVEMENTS Marketing & distribution Product Financial ● evolis ® Professional retail ● Three new evolis® ● Record $2m sales for last partnership in the US with PROFESSIONAL product ranges quarter of CY2017 Neiman Marcus and Soft developed and launched in the US ● Japanese revenue increased Sur
Slide 12: Strong E-commerce Platform
Strong e-commerce Platform • E-commerce considered a strong and essential sales channel globally • Myevolis.com site launched allowing improved online shopping experience • Site upgrade and improved digital marketing and customer services • In Asia Pacific, e-retail sales accounted for 12.1% of reta
Slide 13: Key Growth Drivers - 2018/2019
KEY GROWTH DRIVERS - 2018/2019 Growth is expected to be delivered from the following key areas: • Leverage full AU national sales team (in place since August 2017) • Increased pharmacy distribution with greater profitability • Fillerina® to deliver growth and increase utilisation of existing evolis®
Slide 14: Domestic Sales Channels
DOMESTIC SALES CHANNELS • Targeting full range of products to be stocked in 1,500 pharmacies by July 2018 (<40% of market) • Continue to build an effective national sales team 4% • Incentive system to improve performance Pharmacy • Improve profitability through greater product range • evolis® Profes
Slide 15: International Sales Channels
INTERNATIONAL SALES CHANNELS • Continue with successful television shopping channel, which accounts for 65% of Japanese revenue • Service salon network via Japan’s largest beauty wholesaler, Nichiri, which to date has been particularly successful in men’s barber shops • Two additional areas identifi
Slide 16: International Sales Channels
INTERNATIONAL SALES CHANNELS Sales to be focused on three key channels: • Increase e-commerce activity globally once • E-commerce and TV shopping for Jo-Ju® new website is fully functional (in-house branded lotions digital marketing team, PR) • Pharmacy (evolis®) sales with local • Utilise distribut
Slide 17: New Product Opportunities
NEW PRODUCT Revive & Lift Spray Non-comedogenic dry shampoo, effortlessly refreshes OPPORTUNITIES hair without clogging hair follicles. evolis® Style & Magnify Cream Other Silicone free styling cream opportunities tames hair with touchable opportunities polymers while magnifying each strand’s circum
Slide 18: Market Opportunity
MARKET OPPORTUNITY THE TOTAL ANTI-AGING HAIRLOSS MARKET HAIRCARE forecast to grow is estimated to be US$4B 24% 2018-2022 with emerging markets expected to generate double digit growth ADVANGEN EVOLVIS Operates within the anti-aging outperformed fast haircare segment – given its growing anti-aging ha
Slide 19: Addressing Unmet Market Needs
ADDRESSING UNMET MARKET NEEDS • 80 million men and women are suffering from hair loss in the US • 30,000+ surveyed with over 90% considered fillers, but alone only 10% went ahead – fear of needles - 50% of men experience significant hair loss by age 50 • No other non-injectable transdermal product w
Slide 20: Competitive Landscape
COMPETITIVE LANDSCAPE evolis® is the only anti-aging haircare product that is based on natural ingredients AND is scientifically validated evolis® VS other anti-aging brands • evolis® has significant key points of differentiation from its competitors: ‒ first product with FGF5 technology which actua
Slide 21: Lyramid & Kinera: Midkine in therapy
Lyramid & Kinera Midkine in therapy
Slide 22: Midkine - A Novel and Compelling Target
MIDKINE - A NOVEL AND COMPELLING TARGET Discovered in 1988, midkine is the subject of over 815 publications (300+ in oncology) • Prominent in embryogenesis and wound healing but barely detectable in healthy adults • Elevated levels in most cancers and high MK expression in cancer is strongly prognos
Slide 23: Lyramid & Kinera
LYRAMID & KINERA LYRAMID KINERA • Stage: pre-clinical • Stage: pre-clinical • Drug class: Antibodies CAB101 and CAB102 CDY has the most • Drug Class: Protein, MK (cancer, fibrosis, chronic kidney disease) and significant midkine IP • Applications: heart failure, chronic heart companion diagnostic ma
Slide 24: Milestones Achieved
MILESTONES ACHIEVED Strong progress in pre-clinical development • Secured Australian government funding for pre-clinical kidney program • Continued collaboration of glioblastoma program • Continued collaboration on bone healing program • Commenced preclinical efficacy studies in chronic kidney disea
Slide 25: Objectives for 2018
OBJECTIVES FOR 2018 Complete pre-clinical studies to enter clinical development • CDY has the largest portfolio of midkine IP assets globally with several potential clinical development programs; number of product development opportunities • Clinical indications will be assessed on the strength of p
Slide 26: Business Performance & Outlook
BUSINESS PERFORMANCE & OUTLOOK
Slide 27: Market & Financial Overview
MARKET & FINANCIAL OVERVIEW A0.48$ SHARE PRICE (7 / 3 / 18) (A$3.97M) NPAT (FINANCIAL YEAR ~20% A$27.6M 2017) OWNERSHIP BY MARKET CAP A$5.56M BOARD & (7 / 3 / 18) MANAGEMENT REVENUE (FINANCIAL YEAR 2017) A$3.1M CASH POSITION 1.65M (31 / 12 / 17) UNLISTED OPTIONS (EXECUTIVE)
Slide 28: Financial Performance
FINANCIAL PERFORMANCE 6 Months Ended 31 Dec H1 2018 H1 2017 % chg Comments (A$’Ms) (A$’Ms) Consumer health revenue 3.1 2.0 50.3% • Strong growth, particularly in Japan Midkine & license revenue 0.1 0.1 (1.3)% • Revenue from Pacific Edge license agreement Other income 1.0 0.8 21.9% • Includes R&D tax
Slide 29: Board Members
Board Members Dr David King | Chairman Maria Halasz | CEO and Managing Director An experienced independent chairman with expertise in high With over 24 years in the life sciences sector Maria started in growth companies, David has a track record in building corporate finance before joining Cellmid t
Slide 30: Anticipated Newsflow 2018
Anticipated Newsflow 2018 Targeted Cellmid newsflow in next twelve-months: • Launch of new global website • New product launches • Additional retail partnerships for evolis® in the US and China • Fillerina sales performance and growth • Revenue updates across key markets • Orphan designation of midk
Slide 31: Disclaimer
DISCLAIMER Forward looking statements This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the state